LOUISVILLE, KY., March 2, 2016 -- Appriss Inc., a leading technology provider for risk assessment and analytics in public safety and health care, announced that is has signed an agreement with Marshfield Clinic and facilitate easy integration of opiate prescription histories into electronic medical records (EMRs). The Appriss integration solution provides opiate prescription histories in real-time, at the point-of-care. This increased accessibility is expected to increase prescription monitoring data usage to improve patient safety and combat prescription drug abuse and diversion.
The Appriss secure integration technology provides a variety of options for health IT systems to integrate Prescription Monitoring Program (PMP) data into physician and pharmacist workflows. Physicians and pharmacists currently log into separate websites to retrieve a patient's opiate prescriptions and then cross-reference this data with a patient's health information in other systems. At Marshfield Clinic, the Appriss integration provides instant access to the patient's data within the electronic health records.
"Our Marshfield Clinic physicians have overwhelmingly embraced Appriss' mission of improving prescribing confidence," said Dr. Eric Penniman, East District 4 Medical Director for Primary Care. "Having access to prescription monitoring data directly from within the medication prescribing program has been significant for our physicians and they are universally grateful for this EMR tool."
The benefits of EHR integration and interoperability have long been recognized by Brandeis University's PDMP Center of Excellence (COE). The September 2012 Guidance of PDMP Best Practices recognizes that "integrating PDMP data retrieval with health information exchanges (HIE), electronic health records (EHR), and pharmacy dispensing systems should help reduce the time and effort needed for prescribers and their staff and for pharmacists to access a patient's prescription history." (http://www.pdmpexcellence.org/). The report further details that integration will maximize both the number of users (prescribers and dispensers) receiving the information and the utility for each of those users.
"By providing prescription monitoring data directly at the point-of-care, Marshfield has taken a major step towards improving patient safety in Wisconsin," said Ken Cassell, Vice President of Business Development at Appriss. "Real-time monitoring also saves valuable minutes for providers, helping to ensure the best standard of care for all patients."
For more information about Appriss integration technologies, please visit http://www.appriss.com/pmpgateway.html and http://www.appriss.com/narxcheck.html.
About Appriss
Appriss provides data-driven solutions to fulfill our mission of keeping communities safe and informed. Partnering with public safety, healthcare, and leading private and public companies, Appriss delivers solutions that prevent fraud, mitigate risk, fight crime, ensure compliance, increase public safety and save lives. Appriss' solutions are always backed by excellent customer support with technical agents in the US that are available to help 24x7x365.
For more information, visit www.appriss.com (http://www.appriss.com).
CONTACT: Kathy Sue Bennett
Marketing Manager
Appriss, Inc.
[email protected]


Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



